

26 July 2024

**Cambridge Cognition Holdings plc**  
("Cambridge Cognition", the "Company" or the "Group")

**Issue of Equity and Total Voting Rights**

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that further to the announcement on 12 October 2022 regarding the acquisition of eClinicalHealth Limited ("Clinpal"), the Company has today issued 229,984 new ordinary shares of £0.01 each in the share capital of the Company ("New Ordinary Shares") at an issue price of 132.97 pence per New Ordinary Share to certain shareholders of Clinpal, representing approximately £0.3m of the contingent consideration. No further consideration is due to former shareholders of Clinpal.

**Admission and Total Voting Rights**

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that such Admission will take place on or around 8:00 a.m. on or around 31 July 2024.

In accordance with the provision of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Company confirms that, following the issue of the New Ordinary Shares, its issued ordinary share capital will comprise 41,940,413 Ordinary Shares. There are no shares held in treasury therefore the total number of voting rights in the Company is 41,940,413. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.

**Enquiries:**

**Cambridge Cognition Holdings plc**  
Matthew Stork, Chief Executive Officer  
Stephen Symonds, Chief Financial Officer

Tel: 012 2381 0700  
[press@camcog.com](mailto:press@camcog.com)

**Panmure Liberum Limited (NOMAD and Joint Broker)**  
Emma Earl / Freddy Crossley / Mark Rogers  
Rupert Dearden

Tel: 020 7886 2968  
(Corporate Finance)  
(Corporate Broking)

**Dowgate Capital Limited (Joint Broker)**  
David Poutney / Nicholas Chambers

Tel: 020 3903 7715

**Hudson Sandler (Financial PR and IR)**  
Dan de Belder / Hattie Dreyfus

Tel: 020 7796 4133  
[cog@hudsonsandler.com](mailto:cog@hudsonsandler.com)

**Notes to Editors**

**About Cambridge Cognition**

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit: <https://cambridgecognition.com/>

information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEPPUUCMUPCGQA